Aim: The augmentation of late sodium current (I Na.L ) not only causes intracellular Na + accumulation, which results in intracellular Ca 2+ overload via the reverse mode of the Na + /Ca 2+ exchange current (reverse-I NCX ), but also prolongs APD and induces early afterdepolarizations (EAD), which can lead to arrhythmia and cardiac dysfunction. Thus, the inhibition of I Na.L is considered to be a potential way for therapeutic intervention in ischemia and heart failure. In this study we investigated the effects of tolterodine (Tol), a competitive muscarinic receptor antagonist, on normal and veratridine (Ver)-augmented I Na.L , reverse-I NCX and APD in isolated rabbit ventricular myocytes, which might contribute to its cardioprotective activity. Methods: Rabbit ventricular myocytes were prepared. The I Na.L and reverse-I NCX were recorded in voltage clamp mode, whereas action potentials and Ver-induced early afterdepolarizations (EADs) were recorded in current clamp mode. Drugs were applied via superfusion. Results: Tol (3-120 nmol/L) concentration-dependently inhibited the normal and Ver-augmented I Na.L with IC 50 values of 32.08 nmol/L and 42.47 nmol/L, respectively. Atropine (100 μmol/L) did not affect the inhibitory effects of Tol (30 nmol/L) on Ver-augmented I Na.L . In contrast, much high concentrations of Tol was needed to inhibit the transient sodium current (I Na.T ) with an IC 50 value of 183.03 μmol/L. In addition, Tol (30 nmol/L) significantly shifted the inactivation curve of I Na.T toward a more depolarizing membrane potential without affecting its activation characteristics. Moreover, Tol (30 nmol/L) significantly decreased Ver-augmented reverse-I NCX . Tol (30 nmol/L) increased the action potential duration (APD) by 16% under the basal conditions. Ver (20 μmol/L) considerably extended the APD and evoked EADs in 18/24 cells (75%). In the presence of Ver, Tol (30 nmol/L) markedly decreased the APD and eliminated EADs (0/24 cells). Conclusion: Tol inhibits normal and Ver-augmented I NaL and decreases Ver-augmented reverse-I NCX . In addition, Tol reverses the prolongation of the APD and eliminates the EADs induced by Ver, thus prevents Ver-induced arrhythmia.
Introduction
Previous studies indicated that late sodium current (I Na.L ), which is tetrodotoxin (TTX)-sensitive [1] , was increased under various pathological conditions, such as long QT syndrome III, myocardial hypertrophy, heart failure, ischemia, anoxia, and oxidative stress [2] [3] [4] [5] [6] [7] [8] [9] [10] . Although it has a much smaller amplitude than the transient sodium current (I Na.T ) under normal conditions, I Na.L plays an important role in determining the plateau of action potential (AP) and action potential duration (APD) under the above pathological conditions [11, 12] . The augmentation of I Na.L not only causes intracellular Na + accumulation, which results in intracellular Ca 2+ overload via the reverse mode of the Na + /Ca 2+ exchange current (I NCX ), but also prolongs APD and induces early afterdepolarizations (EAD) [11] [12] [13] [14] [15] [16] [17] , which can lead to arrhythmia and cardiac dysfunction. Thus, the inhibition of I Na.L is considered to be a potential target for therapeutic intervention in ischemia and heart
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Tolterodine reduces veratridine-augmented late I Na , reverse-I NCX and early afterdepolarizations in isolated rabbit ventricular myocytes [1, [11] [12] [13] [18] [19] [20] [21] [22] [23] . Although several compounds, including RSD1235 [24] and AZD7009 [25] , have been reported to block I Na.L , their effective doses were above micromolar [26, 27] . Moreover, these drugs inhibit I Na.L and I Na.T simultaneously, which can induce cardiac conduction block. Currently, only ranolazine has been approved by the FDA as an effective I Na.L blocker for clinical use [3, 13, 18, 28, 29] . GS-458967, another efficient I Na.L specific inhibitor, has not yet been approved for clinical use and was found to have some potential adverse effects to the central nervous system and peripheral nervous system [29] . Thus, more research on high affinity I Na.L blockers is urgently needed.
Tolterodine (Tol), a muscarinic antagonist, is used in the symptomatic treatment of patients with frequent micturition, urgent micturition and urinary incontinence induced by bladder overactivity, with a peak serum concentration of 7-58 nmol/L [30] . Recently, Tol has been reported to affect cardiac ion channels [30, 31] . Kang et al reported that Tol could inhibit HERG channel currents (I Kr on human) expressed on CHO cells and L-type calcium currents (I Ca.L ) in guinea pig ventricular myocytes, with an IC 50 of 17, 143 (1 Hz), and 1084 nmol/L (0.1 Hz), respectively. The APD at 90% repolarization (APD 90 ) was increased by 4%, 8%, and 16%, respectively, in the presence of 3, 10, and 30 nmol/L Tol in guinea pig ventricular myocytes. Based on these results, Kang et al concluded that Tol did not prolong APD significantly because it blocked both HERG and L-type calcium channels, thus offsetting the effects on APD [31] . However, this conclusion needs to be further verified. For example, 30 nmol/L Tol significantly inhibited HERG current but slightly decreased I Ca.L ; thus, in this condition, the prolongation of APD 90 should far exceed 16%, which was different from the reported result of a 16% increase in APD 90 . Furthermore, QT interval prolongation was rarely observed in patients with the application of Tol [32, 33] . We speculate that Tol can inhibit other inward currents associated with APD. Veratridine (Ver) [34] , an activator of I Na.L , is suitable for evoking EAD because it can increase APD to the required extent [35, 36] . Accordingly, this study aims to explore the possible antiarrhythmic mechanisms of Tol by investigating the effects of Tol on normal and Ver-induced I Na.L , reverse I NCX and APD in rabbit ventricular myocytes.
Materials and methods

Cardiomyocyte isolation
Rabbits of either sex, weighing 1500-2000 g, were purchased from the Animal Experimental Center of Wuhan University of Science and Technology, Wuhan, China, and were anesthetized with ketamine (Fujian Gutian Pharmaceutical Co, Ltd, Gutian, Fujian, China, 30 mg/kg iv) and xylazine (Shanghai Shifeng Biological Technology Co, Ltd, Shanghai, China, 7.5 mg/kg im) 10 min after an intravenous injection of 2000 U of heparin. All efforts were made to minimize animal discomfort and suffering during the experimental process. The heart was excised and retrogradely perfused on a modified 
Whole-cell patch-clamp technique
The conventional whole-cell patch-clamp technique using an EPC-10 amplifier (HEKA Electronic, Lambrecht, Germany) was applied to record transmembrane potentials and ion currents in either current clamp or voltage clamp mode. Patch electrodes were pulled with a two-stage puller (PP-83, Narishige Group, Tokyo, Japan), and their resistances were in the range of 1.0-1.5 MΩ after filling with pipette solution. An 80% compensation of series resistance was achieved without ringing. Currents were filtered at 2 kHz, digitized at 10 kHz, and stored on a computer hard drive for further analysis. All experiments were performed at room temperature (22-24 °C). The current-voltage (I-V) relationship of I Na.L was determined by 300 ms depolarizing pulses to potentials ranging from -90 mV to +40 mV in 10 mV increments from a holding potential of -120 mV. I Na.L was measured at the 200 ms of the depolarizing pulse to avoid the influence of I Na.T on I Na.L [37] . The voltage dependence of steady-state inactivation for I Na.T was determined using 100 ms conditioning pulses from a holding potential of -120 mV, ranging from -100 mV to -45 mV in 5 mV increments, followed by a test pulse to -10 mV for 100 ms. The voltage dependence of steady-state activation for I Na.T was determined using a holding potential of -120 mV, ranging from -90 mV to +60 mV in 5 mV increments. The maximum value of I Na.T was measured. The I NCX was induced by a ramppulse protocol ranging from +60 mV to -120 mV continuing for 2000 ms from a holding potential of -40 mV. I NCX was measured as the current sensitive to 5 mmol/L Ni 2+ at +50 and -100 mV. AP was recorded in current clamp mode by using whole-cell patch-clamp techniques and was evoked by depolarizing current pulses (5 ms duration, 1.5 times the threshold intensity, 0.25 Hz) in ventricular myocytes. Drugs and reagents TTX and collagenase type I were provided by Tocris (Ellisville, MO, USA) and Gibco (Invitrogen, Paisley, UK), respectively. BSA, taurine, and HEPES were purchased from Roche (Basel, Switzerland). All other chemicals were obtained from Sigma Chemical (Saint Louis, MO, USA). Tol and Ver were stored in the dark at room temperature and -20 °C, respectively. On the day of experimentation, these two drugs were dissolved in dimethyl sulfoxide to create stock solutions from which test solutions were made. The stock solution was diluted with cell external solution to achieve the desired final concentrations immediately before the experiments. The final concentration of dimethyl sulfoxide was less than 0.1%. When the two drugs were used sequentially in an experiment, we applied the second drug after the effect of the first drug achieved a stable level.
Data analysis
All data are presented as the mean±SD and were analyzed using FitMaster (v2x32, HEKA) and SPSS 13.0 software. Current density (pA/pF), ie, the amplitude of the current divided by membrane capacitance, was used for analysis. Figures were plotted with Origin (V7.5, OriginLab Co, MA, USA). Student's t-test was used to determine the difference between two groups of data. Statistical analysis was performed using oneway analyses of variance (ANOVA), followed by the Scheffé test for multiple comparisons. A P-value<0.05 was considered statistically significant. Current tracings were fitted using Hill or Boltzmann functions with Origin 7.5. The fractional blockade was calculated using the following equation: Fractional blockade=(I control -I drug )/I control , where I control and I drug are the current amplitudes in the absence and presence of Tol, respectively. Concentrationeffect curves were fitted using the Hill equation as follows:
n ], where B max was the maximum blockade of currents, IC 50 was the concentration of Tol for half-maximum blockade, D was the concentration of Tol, and n was the Hill coefficient. For all IC 50 values, all current levels were measured at -20 mV.
Steady-state activation data and inactivation relationships of I Na.T were fitted to the Boltzmann equation as follows: Y=1/ [1+exp(V m -V 1/2 )/k], where V m was the membrane potential, V 1/2 was the half-activation or half-inactivation potential, and k was the slope factor. For the steady-state activation and inactivation curve, Y stood for the relative conductance (G/G max ) and relative current (I/I max ), respectively.
Results
Effects of Tol on I Na.L under normal conditions I Na.L was recorded with 300 ms voltage steps from a holding potential of -120 mV to -20 mV at 0.5 Hz. After the application of 4 μmol/L TTX, I Na.T did not change significantly, whereas I Na.L was almost completely blocked with densities changing from 0.335±0.017 to 0.076±0.012 (n=8, P<0.01 vs control; Figure  1 ). In addition, the increased currents induced by 20 µmol/L Ver (from 0.253±0.015 to 1.613±0.032) were almost completely blocked by 4 µmol/L TTX (0.081±0.009; n=6, P<0.01 vs 20 µmol/L Ver; Figure 1A ). These results showed that the increased recorded currents were exactly I Na.L ( Figure 1A) .
The current-voltage relationship of I Na.L was recorded. Tol Effects of atropine on increased I Na.L induced by Ver We studied whether the blocking effect of Tol on I Na.L was achieved by its binding to the muscarinic (M) receptor. Atropine, a high-performance M receptor antagonist, was used. After the application of 20 µmol/L Ver, the current density of I Na.L was increased from 0.310±0.008 pA/pF to 1.668±0.048 pA/pF (n=8, P<0.01) and was not significantly changed after giving 100 µmol/L atropine (1.656±0.039 pA/pF, n=8, P>0.05 vs Ver). However, after the application of 30 nmol/L Tol, the current density of I Na.L was decreased to 0.689±0.019 pA/pF (n=8, P<0.01 vs atropine, Figures 2F) . These results indicated that Tol's blockade of I Na.L was independent of its effect on the M receptor signaling pathway.
Effects of Tol on I Na.T At concentration of 1 μmol/L Tol did not change the density of I Na.T (n=10, P>0.05 vs control), whereas 10, 30, 100, and 300 μmol/L Tol decreased the magnitudes of I Na.T in a concentration-dependent manner ( Figure 3A ). The suppression rates of I Na.T (at -20 mV) were 14.2%±2.3% (n=10, P<0.05 vs 1 µmol/L Tol), 25.8%±5.3% (n=10, P<0.01 vs 10 µmol/L Tol), 43.7%±5.4% (n=10, P<0.01 vs 30 µmol/L Tol), and 55.3%±6.8% (n=10, P<0.05 vs 100 µmol/L Tol) at 10, 30, 100, and 300 µmol/L Tol, respectively, and the value of IC 50 was 183.03 µmol/L ( Figures  3A, 3B) .
The steady-state activation and inactivation curves for I Na.T were also examined. For the steady-state activation of I Na.T , the -5C ). In another group experiment, 4 µmol/L TTX also inhibited the increased forward and reverse I NCX induced by Ver (Figures 5D-5F ).
Effects of Tol on AP
The experiments were divided into four groups. In group 1, 30 nmol/L Tol prolonged APD 90 to some extent (n=12, P<0.05 vs control) ( Figure 6A , Table 1 ). In group 2, 200 nmol/L E-4031 (an I kr specific antagonist) significantly prolonged APD 90 (n=12, P<0.05 vs control) and 30 nmol/L Tol plus E-4031 further extended APD 90 slightly (n=12, P>0.05 vs E-4031) ( Figure  6B , Table 1 ). In group 3, 20 µmol/L Ver significantly extended APD 90 and evoked EAD in 18 of 24 cells (75%). In the presence of Ver, 30 nmol/L Tol reversed APD 90 and eliminated EADs induced by Ver from 18/24 to 0/24 cells ( Figure 6C , Table 2 ). In group 4, the myocytes were sequentially treated with no drug (control), 20 µmol/L Ver, and Ver plus 4 µmol/L TTX. TTX also shortened the prolongation of APD 90 (n=12, P<0.05 vs Ver) and eliminated EADs induced by Ver from 8/12 to 0/12 ( Figure 6D , Table 2 ). In all groups, Tol had no effect on the resting potential, AP amplitude and V max (Tables 1, 2 ). V max , maximum rate of depolarization; APD 90 , action potential duration at 90% repolarization. 
Discussion
Tol, a competitive, nonselective antimuscarinic compound, is developed for the treatment of an overactive bladder [32, 38, 39] . Millions of patients have benefited from Tol treatment [40] . Furthermore, little has been reported regarding the fatal proarrhythmic effects of Tol in either early clinical tests or follow-up studies [32, 33, 38, 41] . In recent years, studies have shown that Tol can reduce heart rate variability, while its effect on arrhythmia remains unknown [42, 43] . In this study, Tol inhibited normal and Ver-augmented 2 ). In the presence of atropine, 30 nmol/L Tol also decreased the enlarged I Na.L induced by Ver, which demonstrated that its blocking effects on I Na.L were not a result of M receptor signaling pathway blockage ( Figure 2F ). Tol did not modify the steady-activation curve but shifted the steady-inactivation curve of I Na.T toward a more positive voltage, which indicated that Tol accelerated the rate of inactivation of sodium channels ( Figure 4D ). Tol also inhibited I Na.T in a concentration-dependent manner (Figure 4 ). In contrast with an IC 50 of 32.08 nmol/L for I Na.L , the IC 50 for I Na.T was 183.03 µmol/L, which indicated that Tol specifically inhibited I Na.L . The ratio of suppressions of I Na.L and I Na.T (IC 50 I Na.T /IC 50 I Na.L ) was 5705, compared with values of 38 and 2.7 for ranolazine and lidocaine, respectively [18] , which shows that Tol has a high affinity blockade effect on I Na.L . Thus, selectively inhibiting I Na.L with only negligible effect on I Na.T at nmol/L concentration, Tol could have little effect on membrane depolarization, cell excitability and conductibility, thereby preventing arrhythmogenic and other adverse effects.
Under pathological conditions, the increase in I Na.L results in a rise of intracellular Na + and subsequent intracellular Ca 2+ overload by increasing reverse I NCX . The accumulation of Ca 2+ can cause cell injury, electrical activity disorder and ventricular systolic dysfunction, which aggravates myocardial ischemia and hypoxia. The entire process can develop into a vicious circle [3, 4, 13, 14] . Our previous study indicates that 2 µmol/L TTX (no report regarding its effects on ion channels except I Na.L ) suppresses the reverse I NCX under normal and hypoxic conditions by inhibiting I Na.L [11] . In this study, Tol inhibited the reverse I NCX increased by Ver (Figures 5A-5C ). Therefore, we speculate that Tol can protect myocytes from injury by preventing abnormal Ca 2+ influx caused by the increase in reverse I NCX .
Kang et al [31] reported that Tol blocked both the HERG channels and L-type Ca 2+ channels simultaneously but did not significantly prolong APD, (a maximal 16% extension of APD 90 ). In their study, 30 nmol/L Tol significantly inhibited HERG current but slightly decreased Ca 2+ current. According to these results, APD 90 should have been prolonged significantly, which would be markedly different from their report of just a 16% extension of APD 90 . In our present study 30 nmol/L Tol blocked normal and Ver-increased I Na.L . In our AP study, 30 nmol/L Tol extended APD 90 by 16% under normal conditions, which was consistent with the result reported by Kang et al, and had little effects on the prolongation of APD induced by E-4031 ( Figure 6B and Table 1 ). Based on the above-mentioned results, we speculate that Tol's simultaneous inhibition of I Kr and I Na.L can explain the fact that 30 nmol/L Tol weakly prolonged the APD in normal ventricular myocytes. Ver significantly extended APD 90 and evoked EAD in 18 of 24 cells (75%). In the presence of Ver, 30 nmol/L Tol reversed APD 90 and eliminated EADs induced by Ver ( Figure 6C and Table 2 ), which indicates that Tol inhibits arrhythmia induced by Ver. As a multi-ion channel blocker, Tol has complex electrophysiological properties. It is possible that Tol inhibits arrhythmias by inhibiting I Na.L , reversing prolongation of APD 90 and eliminating EADs induced by Ver.
In conclusion, Tol inhibited normal and Ver-increased I Na.L in a concentration-dependent manner and decreased Veraugmented reverse I NCX . In addition, Tol reversed the prolongation of APD and eliminated EADs induced by Ver. These findings point to the potential of Tol as a high affinity I Na.L blocker to inhibit arrhythmias induced by increased I Na.L with few undesirable adverse effects.
